


# Adoptive T-cell therapy - Solutions for T-cell engineering and expansion

Cornelia Hampe, PhD

Senior Product Manager & Scientific Support Specialist

# Adoptive T cell-based therapies




June CH et al. Science Translational Medicine 2015: Vol. 7, Issue 280, pp. 280ps7

## Three main approaches:

- **Expansion/enrichment** of tumor-infiltrating lymphocytes (**TILs**)
- **Engineering** of PBMCs with T-cell receptors (**TCRs**)
- **Engineering** of PBMCs with chimeric antigen receptors (**CARs**)


# Autologous vs. Allogeneic cell therapies

- **Autologous treatments:** use a person's own cells
- **Allogeneic treatments** use cells from a healthy donor whose human leukocyte antigens (HLA) match the patient's HLA → off the shelf solutions



[Graham et al., 2018](#)

# Adoptive T-cell therapies



- Although T cells can be isolated from blood and grown *ex vivo*, large-scale T cell expansion is still challenging
- Takara Bio offers a **complete solution** for T-cell stimulation, transduction and expansion

# Tools for T-cell expansion & transduction

- Benefits of the combined use:
  - Highly efficient expansion of T cells
  - Greater proportion of naïve-like T cells (CD45RA<sup>+</sup>/CCR7<sup>+</sup> phenotype) with high therapeutic potential



LymphoONE Medium  
WK52S/WK552



Anti-CD3 antibody  
T210



RetroNectin Reagent  
T100A/B, T202




CultiLife Culture Bag  
FU0005/FU0010

# T-cell activation

- Anti-CD3 mAb GMP grade
  - Clone OKT3 (mouse IgG2a)
  - GMP-grade, suitable for *ex vivo* cell culture and gene therapy studies


- RetroNectin Reagent:

- Recombinant human fibronectin fragment (rFN-CH-296)
- Increases T-cell expansion via binding to **integrins** (VLA-4, VLA-5) expressed on T cells
- Research-grade and GMP-grade versions available




# Combined RetroNectin/anti-CD3 stimulation

- Higher fold expansion with RN/ $\alpha$ CD3 stimulation compared to other protocols
- Greater proportion of naïve-like T cells (CCR7+/CD45RA+ phenotype)




**Higher fold expansion**




**Greater proportion of naïve-like T cells**

# Preservation of naïve-like phenotype



Increased CD8+ population compared to CD3/CD28 stimulation



CM: central memory  
EM: effector memory  
TdEM: terminally differentiated effector memory

Greater proportion of naïve-like T cells (CCR7+/ CD45RA+)

Yu SS et al. *In vivo* persistence of genetically modified T cells generated *ex vivo* using the fibronectin CH296 stimulation method. *Cancer Gene Therapy*. 2008; 15: 508–516.



# *In vivo* persistence of genetically modified T cells


- Engineered T cells were transplanted into NOD/SCID mice, and mice were killed 14 days later. **High engraftment efficiency** for all groups observed.
- The **infiltration of human cells** into the bone marrow and thymus was significantly **higher** with the **anti-CD3/FN-CH296 group** than that with the anti-CD3 group.

<b>Group</b>	<b>Days</b>	<b>PBL (%)</b>	<b>Bone marrow (%)</b>	<b>Thymus (%)</b>	<b>Spleen (%)</b>
Anti-CD3	7	90.0 (87.6–93.9)	ND	ND	ND
	14	95.1 (92.2–98.0)	69.5 (63.7–79.9)	67.0 (24.3–94.1)	97.9 (96.3–99.3)
Anti-CD3/anti-CD28	7	92.1 (89.4–95.6)	ND	ND	ND
	14	98.8 (97.9–99.4)	88.4 (81.0–93.6)	89.0 (67.2–96.6)	99.0 (98.7–99.4)
Anti-CD3/FN-CH296	7	94.2 (92.6–95.5)	ND	ND	ND
	14	98.2 (97.0–99.2)	79.3 (69.7–97.5)	83.4 (70.1–96.0)	98.5 (97.8–99.1)

Yu SS et al. *In vivo* persistence of genetically modified T cells generated *ex vivo* using the fibronectin CH296 stimulation method. *Cancer Gene Therapy*. 2008; 15: 508–516.


# Improved multifunctionality of CD8<sup>+</sup> T cells

- **RetroNectin stimulation** in the initial *in vitro* expansion of tumor-reactive T cells improves **CD8<sup>+</sup> T-cell (cytotoxic lymphocyte) multifunctionality**.



Hosoi H et al. Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8<sup>+</sup> T cells. Eur J immunol. 2014; 44:1747-1758

# Ag-specific cytotoxicity of CD8<sup>+</sup> T cells



After 7 days of stimulation, lymphocytes were mixed with allogeneic or autologous PHA-blast target cells at effector/target ratios of 90 and 30. Cytotoxicity was assessed by a calcein-AM release assay.

Human T cells stimulated with anti-CD3 mAb plus CH-296 exhibited **higher cytotoxicity against allogeneic target cells** than T cells stimulated with anti-CD3 mAb alone or anti-CD3 and anti-CD28 mAbs


Hosoi H et al. Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8<sup>+</sup> T cells. Eur J immunol. 2014; 44:1747-1758

# LymphoONE T-Cell Expansion Xeno-Free Medium

- Improved version of GT-T551 medium, specifically formulated for *ex vivo* human T-cell expansion and transduction
- Suitable for serum-free T-cell expansion
- Xeno-free, serum-free, chemically defined medium
- Supplemented with human serum albumin, human insulin, L-glutamine, and streptomycin
- GMP-grade version (w/o antibiotics) expected for Q4, 2019




# RetroNectin expansion protocol in LymphoONE medium



Higher fold expansion in LymphoONE compared to other media

T-cell expansion via stimulation by RetroNectin, anti-CD3 mAb, and IL-2

# RetroNectin expansion protocol in LymphoONE medium



Greater proportion of naïve-like T cells (CD45RA+/CCR7+ phenotype) compared to other media


T-cell expansion via stimulation by RetroNectin, anti-CD3 mAb, and IL-2

# Large-scale expansion using CultiLife culture bags

- A **sterile, closed system** - reduces the risk of culture contamination and user infection
- **Gas permeable** and **transparent** (suitable for visual inspection of cells via microscopy)
- Available in **two sizes** (215 cm<sup>2</sup> and 640 cm<sup>2</sup>)
- CultiLife 215 bags can be **coated with RetroNectin** for T-cell activation and transduction




# RetroNectin Expansion Protocol in culture bags





# Adoptive T-cell Therapy



## Classical CAR/TCR engineering



- In-Fusion cloning
- Retroviral or lentiviral delivery
- RetroNectin transduction enhancer

## Refinement of cell engineering (CRISPR/Cas9)

- Targeted CAR integration
- KO of specific genes
- Footprint-free engineering


# T-cell engineering using viral delivery

- Cloning into retroviral/lentiviral vectors
  - A broad portfolio of [viral vectors](#)
  - [High fidelity](#) DNA Polymerases (PrimeSTAR Max, PrimeSTAR GXL)
  - [In-Fusion HD](#) technology for highly efficient, seamless [cloning](#)



# T-cell engineering using viral delivery



- Production of viral particles (Lenti-X and Retro-X portfolios)
  - **Packaging:**
    - Lenti-X Packaging Single Shots (VSV-G): convenient, lyophilized format - 4<sup>th</sup> generation
    - Retro-X Universal Packaging System: p10A1, pAmpho, pEco, or pVSV-G envelope
  - **Titration:**
    - Retro-X or Lenti-X qRT-PCR Titration Kit: Accurate titration in 4 hr
    - Lenti-X GoStix Plus: Quantitative output in only 10 minutes
    - Lenti-X p24 Rapid Titer Kit: ELISA-based titration
    - Lenti-X Provirus Quantitation Kit: Integrated copy number quantification via qPCR
  - **Concentration:**
    - Retro-X or Lenti-X Concentrator: 100-fold concentration without ultracentrifugation
  - **Purification:**
    - Lenti-X Maxi Purification Kit: Column-based method, high yield and purity
  - **Integration Site Analysis**
    - Lenti-X or Retro-X Integration Site Analysis Kit: Identify the exact site of integration



# Transduction of hematopoietic cells

- RetroNectin Recombinant Human Fibronectin Fragment

- Enhances lentiviral/retroviral transduction by **aiding the colocalization** of target cells and viral particles
- **GMP-grade** version available



**Higher transduction efficiencies** in CD8+ cells with RetroNectin compared to Polybrene, especially at low MOI (90X dilution).

# Transduction of hematopoietic cells

OPEN ACCESS Freely available online


PLoS one

## Towards a Clinically Relevant Lentiviral Transduction Protocol for Primary Human CD34<sup>+</sup> Hematopoietic Stem/Progenitor Cells

Michelle Millington, Allison Arndt, Maureen Boyd, Tanya Applegate, Sylvie Shen\*

Johnson and Johnson Research Pty Ltd., Eveleigh, New South Wales, Australia


- **Retronectin (RN)** combined with **spinoculation** resulted in the highest transduction efficiency (34.1%)
- **RetroNectin reagent alone** resulted in a statistically significant increase in transduction rate (24.6%)
- No advantage of spinoculation alone (10% of cells transduced)



# Use of RetroNectin GMP in clinical trials

- Used in over **68 protocols for clinical trials**, at 44 institutions worldwide:
  - **Metastatic Synovial Cell Sarcoma and Melanoma:** Transduction of patient-derived lymphocytes with TCR/CAR genes that recognize cancer antigens (e.g., MART-1, gp100, or NY-ESO-1) for therapy (Robbins et al. 2011, J Clin Oncol 29:917-92).
  - **Multiple Myeloma:** Anti-BCMA CAR T cells (Ali, S. A. *et al.* 2016 *Blood* **128**, 1688–1700).
  - **B-cell malignancies (Follicular lymphoma, CLL):** Transduction of patient derived T-cells with anti-CD19-CAR (Kochenderfer et al., 2012, Blood 119(12):2709-20).
  - **B cell acute lymphoblastic leukemia (B-ALL):** Five relapsed B-ALL subjects have been treated with autologous T cells expressing a CD19-specific CD28/CD3 $\zeta$  second-generation dual-signaling chimeric antigen receptor (CAR) termed 19-28z (Brentjens RJ et al., 2013, Sci Transl Med. 5(177):177ra38)

# Adoptive T-cell Therapy



## Classical CAR/TCR engineering

- In-Fusion cloning
- Retroviral or lentiviral delivery
- RetroNectin transduction enhancer

## Refinement of cell engineering (CRISPR/Cas9)

- Targeted CAR integration
- KO of specific genes
- Footprint-free engineering

# The promise of CRISPR/Cas9 genome editing

- Improve CAR expression / avoid insertional oncogenesis:
  - Site-specific integration of CAR/TCR constructs
- Prevent T-cell exhaustion due to inhibitory receptors (immune checkpoints):
  - Knockout of PD-1, CTLA-4, or LAG-3 receptors
- Prevent graft-versus-host disease (GvHD):
  - Knockout TCR
- Prevent host rejection:
  - Knockout HLA or B2M

Key requirements for  
allogeneic, off-the-shelf  
solutions




# Footprint-free T-cell engineering

- **Guide-it tools for CRISPR/Cas9 gene editing**
  - Guide-it Recombinant Cas9 (Electroporation-Ready):
    - High concentration and **low glycerol**
  - Guide-it sgRNA *In Vitro* Transcription Kit & Screening Kit:
    - Produce sgRNAs using IVT and **screen for efficacy**
  - Guide-it Long ssDNA Production System
    - Produce **ssDNA repair templates** up to 5 kb
    - **Higher knockin specificity** compared to dsDNA templates
    - **Lower toxicity** compared to dsDNA templates



Electroporation of RNP complexes (and ssDNA HDR template) for KO/KI




# Footprint-free T-cell engineering

Letter | Published: 11 July 2018

## Reprogramming human T cell function and specificity with non-viral genome targeting


Theodore L. Roth, Cristina Puig-Saus, [...] Alexander Marson 

*Nature* 559, 405–409 (2018) | [Download Citation](#) 

- Knockin of sequences encoding a TCR specific to the NY-ESO-1 antigen at the *TCR $\alpha$*  locus using **electroporation of RNP complexes**
- Evaluation of **long ssDNA repair templates** vs dsDNA


# Footprint-free T-cell engineering

## ssDNA is less toxic



*At 4 days post-electroporation, long ssDNA HDR templates (~1.3 kb) did not show the decreasing viability in CD3+ T cells electroporated with a linear dsDNA HDR template of the same length.*


## ssDNA is more specific



*ssDNA HDR templates reduced functional off-target integrations approximately 100-fold, while maintaining efficient on-target integration.*

Roth TL et al., Nature 2018; 559:405–409.

# Adoptive T-cell Therapy




- Quality Control**
- Mycoplasma
  - RetroNectin EIA Kit
  - Virus detection (copy number, integration site)

# Quality Testing of engineered T cells

- **Mycoplasma Detection**
  - TaKaRa PCR Mycoplasma Detection Set
- **RetroNectin Detection**
  - RetroNectin EIA Kit: quantitative determination of **release from RetroNectin-coated plates** and **residual RetroNectin levels** in cryopreservation solutions of cells cultured or transduced in the presence of RetroNectin
- **Provirus copy number detection (qPCR)**
  - Provirus Copy Number Detection Primer Set, Human (for Real Time PCR) & Cycleave PCR Core Kit (MMLV-derived Retrovirus)
  - Lenti-X Provirus Quantitation Kit
- **Integration Site Analysis**
  - Retro-X Integration Site Analysis Kit
  - Lenti-X Integration Site Analysis Kit

# Adoptive T-cell Therapy



## Immune repertoire analysis

- SMARTer TCR profiling

## Transcriptomic analysis

- SMARTer RNA-seq portfolio
- qPCR portfolio

## DNA-seq

- ThruPLEX
- PicoPLEX



# TCR Profiling

- Determining T-cell repertoires in cancer patients
  - Upstream of a CAR-T workflow: biomarker discovery
- Identifying tumor-reactive T-cell clones
- 5' RACE-based approach that captures full-length sequence information for entire variable regions of TCR- $\alpha$  and TCR- $\beta$  subunits
  - SMARTer Human TCR a/b Profiling Kit
  - SMARTer Human single cell TCR a/b Profiling Kit
  - SMARTer Mouse TCR a/b Profiling Kit



# Transcriptional Profiling / DNA-seq


- SMART-Seq kits
  - **Single-cell mRNA-seq**: solutions for mRNA-seq with ultra low inputs
  - **Total RNA-seq**: identification of both non-coding and coding RNAs
  - **Small RNA-seq**: miRNAs, siRNAs, piRNAs, snpRNAs
- qRT-PCR portfolio
  - **One-step** or **two-step** RT-qPCR kits
  - Probe-based or TB Green dye-based
- DNA-seq kits
  - **ThruPLEX Plasma-seq / ThruPLEX Tag-seq Kits**: cell-free DNA sequencing
  - **PicoPLEX Gold**: analysis of tumor burden (CTCs)





# Summary – T-cell stimulation & expansion

- Benefits of the combined use:
  - Highly efficient expansion of T cells
  - Greater proportion of naïve-like T cells (CD45RA<sup>+</sup>/CCR7<sup>+</sup> phenotype) with high therapeutic potential



LymphoONE Medium  
WK552S/WK552



Anti-CD3 antibody  
T210




RetroNectin Reagent  
T100A/B, T202



CultiLife Culture Bag  
FU0005/FU0010

# Additional tools for T-cell engineering and analysis

- TCR/CAR vector construction:
  - Viral vectors
  - In-Fusion cloning
  - PrimeSTAR Max Polymerase
- Viral transduction:
  - Packaging, Titration
  - Concentration, Purification
  - RetroNectin transduction enhancer
  - Integration Site Analysis
- CRISPR-mediated T-cell engineering:
  - Recombinant Cas9
  - sgRNA IVT Kit
  - Long ssDNA Production System



- TCR profiling:
  - SMARTer Human TCR a/b Profiling Kit
  - SMARTer Human scTCR a/b Profiling Kit
- Transcriptional profiling:
  - SMART-Seq kits
  - qPCR portfolio
- DNA-seq
  - ThruPLEX, PicoPLEX Gold

that's  
**GOOD**  
science!®

---

Clontech **TakaRa** cellartis